Study rationale and baseline data for pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer's dementia (THC-AD).

导出 LinkOut

翻译打印收藏纠错

作者： Leah M,Cohen ^[1] ; Eleanor,Ash ^[1] ; John D,Outen ^[2] ; Ryan,Vandrey ^[2] ; Halima,Amjad ^[3] ; Marc,Agronin ^[4] ; M Haroon,Burhanullah ^[2] ; Patricia,Walsh ^[5] ; James M,Wilkins ^[6] ; Jeannie-Marie,Leoutsakos ^[7] ; Milap A,Nowrangi ^[2] ; David,Harper ^[6] ; Paul B,Rosenberg ^[2] ; Brent P,Forester ^[6]

作者单位： Division of Geriatric Psychiatry, McLean Hospital, Belmont, MA, USA. ^[1] Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ^[2] Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ^[3] Department of Mental Health and Clinical Research, Miami Jewish Health, Miami, FL, USA. ^[4] Department of Psychiatry, North Shore Medical Center, Salem, MA, USA. ^[5] Division of Geriatric Psychiatry, McLean Hospital, Belmont, MA, USA.;Harvard Medical School, Boston, MA, USA. ^[6] Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.;Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. ^[7]

关键词 Alzheimer’s disease agitation dementia drug trials neuropsychiatric symptoms